SCHEMBL718485

SCHEMBL718485

CCOC(=O)CCN(C)C(=O)c1ccc(NC(c2oc3cc(F)ccc3c2C)C2CCCCC2)cc1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CB P42338 1/20 0.35
MEN1 O00255 2/20 0.34
KMT2A Q03164 2/20 0.34
IDH1 O75874 1/20 0.34
ALDH1A1 P00352 4/20 0.34
KDM4E B2RXH2 3/20 0.34
HSD17B10 Q99714 3/20 0.34
GLA P06280 2/20 0.34
CASP1 P29466 2/20 0.34
CASP7 P55210 2/20 0.34
HPGD P15428 2/20 0.34
GAA P10253 1/20 0.34
NPC1 O15118 1/20 0.34
RAB9A P51151 1/20 0.34
NAMPT P43490 3/20 0.33
MAPT P10636 2/20 0.33
LMNA P02545 1/20 0.33
THRB P10828 1/20 0.33
HTT P42858 1/20 0.33
ATM Q13315 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL716825 0.94 NPC1 (0.41) PIK3CBMEN1KMT2AIDH1ALDH1A1
SCHEMBL718275 0.93 RAB9A (0.40) PIK3CBMEN1KMT2AIDH1ALDH1A1
SCHEMBL3403389 0.91 NPC1 (0.36) PIK3CBNPC1RAB9ANAMPTTEAD4
SCHEMBL10284489 0.91 NPC1 (0.36) PIK3CBNPC1RAB9ANAMPTTEAD4
SCHEMBL719968 0.89 NPC1 (0.38) MEN1KMT2AALDH1A1KDM4EHSD17B10
SCHEMBL718770 0.88 KMT2A (0.35) MEN1KMT2AALDH1A1KDM4EHSD17B10
SCHEMBL718427 0.88 KMT2A (0.35) PIK3CBMEN1KMT2AIDH1ALDH1A1
SCHEMBL718999 0.87 NPC1 (0.36) PIK3CBMEN1KMT2AIDH1ALDH1A1
SCHEMBL719320 0.87 NPC1 (0.35) PIK3CBMEN1KMT2AIDH1ALDH1A1
SCHEMBL718115 0.86 PIK3CB (0.35) PIK3CBMEN1KMT2AIDH1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8436043-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-05-07 US disclosed
US-20120270865-A2 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-10-25 US disclosed
US-20120053173-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-03-01 US disclosed
EP-2251326-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2010-11-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120053173-A1 HETEROCYCLIC COMPOUND SLC5A2, SLC5A1, IAPP PIK3CB 3850/4885MEN1 444/4885KMT2A 1298/4885
US-20120270865-A2 HETEROCYCLIC COMPOUND SLC5A2, SLC5A1, IAPP PIK3CB 3850/4885MEN1 444/4885KMT2A 1298/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.